Overview * Ginkgo Q2 2025 rev falls to $50 mln, down from $56 mln yr/yr * Cell Engineering rev rises 8% to $39 mln, driven by biopharma growth * Biosecurity rev declines to $10 mln from $20 mln yr/yr * Co achieves $250 mln cost-reduction target ahead of schedule Outlook * Ginkgo reaffirms 2025 total revenue of $167-$187 mln * Ginkgo expects 2025 Cell Engineering revenue of $117-$137 mln * Ginkgo expects 2025 Biosecurity revenue of at least $40 mln * Ginkgo aims for Adjusted EBITDA breakeven by end of 2026 Result Drivers * CELL ENGINEERING GROWTH - Cell Engineering revenue rose 8% to $39 mln, driven by demand from biopharma and government customers * BIOSECURITY DECLINE - Biosecurity revenue fell to $10 mln, impacted by reduced demand compared to prior year * COST REDUCTION - Achieved $250 mln annualized cost-reduction target ahead of schedule, aiding improved adjusted EBITDA Key Details Metric Beat/Mis Actual Consensu s s Estimate Q2 Rev $50 mln Q2 EPS -$1.1 Q2 Net -$60.30 Income mln Q2 $115.14 Operatin mln g Expenses Q2 -$65.54 Operatin mln g Income Q2 -$60.58 Pretax mln Profit Analyst Coverage * The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy", no "hold" and 3 "sell" or "strong sell" * The average consensus recommendation for the biotechnology & medical research peer group is "buy." * Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $8.00, about 74.5% below its August 6 closing price of $13.96 Press Release: (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

https://www.marketscreener.com/news/ginkgo-bioworks-q2-revenue-falls-11-ce7c5edcd881f224